Ipsen To Acquire Memo Therapeutics In Deal Worth Over 700m
Ipsen to acquire Memo Therapeutics in deal worth over €700M
Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn - PMLiVE
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal ...
Ipsen to Acquire Kartos Therapeutics in Major Oncology Deal
Ipsen to Acquire Kartos Therapeutics in Major Oncology Deal
Ipsen to Acquire Kartos Therapeutics in Major Oncology Deal
Ipsen to Acquire Kartos Therapeutics in Major Oncology Deal
Ipsen to acquire Memo Therapeutics – Ysios Capital
Ipsen to Acquire Memo Therapeutics for >€700M - PharmaShots
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK ...
Advertisement Space (300x250)
Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million - WSJ
Ipsen to acquire Memo Therapeutics for up to EUR 700 million
Ipsen to Acquire Memo Therapeutics for >€700M - PharmaShots
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK ...
Ipsen to acquire Memo Therapeutics for up to EUR 700 million
Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining ...
Ipsen to acquire Sanofi assets in $88 million deal - Pharmafile
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK ...
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK ...
Ipsen strikes second M&A deal this week, with Memo Therapeutics buy ...
Advertisement Space (336x280)
Ipsen Acquires Memo Therapeutics in €700M+ Rare Disease Deal, Adding ...
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in ...
Ipsen to acquire ImCheck Therapeutics For €1B - USA Herald
Ipsen announces its intention to acquire ImCheck Therapeutics ...
Switzerland: Memo Therapeutics to be acquired by Ipsen for a total ...
Ipsen to Acquire Epizyme - Growth in Oncology | Ipsen Global | Ipsen
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a ...
Ipsen rachète Memo Therapeutics pour 200 M€, jusqu'à 700 M€ avec les jalons
Ipsen bolsters rare disease pipeline in €700m Memo takeover
Ipsen's M&A team strikes again, adding Memo in $700m deal | pharmaphorum
Advertisement Space (336x280)
Ipsen Acquires Memo Therapeutics for BKPyV Antibody Potravitug | Pharma Now
Ipsen secures rights to preclinical T cell engager in $610M pact with ...
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion - WSJ
Ipsen enters $610m licensing deal with Biomunex to advance MAIT-cell ...
Ipsen acquiert Memo Therapeutics pour un montant initial de 200 ...
Ipsen licenses Simcere ADC in $1bn-plus deal | pharmaphorum